From Quandary to Clarity in Relapsed/Refractory
Multiple Myeloma: Optimizing Treatment and
Empowering Patients

A Three-Part Educational Series for Oncology Advanced Practitioners

Multiple myeloma (MM), a hematologic malignancy plagued by multiple relapses, has seen notable progress in care that has led to improved survival. Contributing to the progress has been an increased understanding of MM pathogenesis and cytogenetics-based risk stratification, and the availability of therapeutics such as immunomodulatory drugs, proteasome inhibitors, and novel targeted therapies. With the rapid pace of advances in MM, management of patients with relapsed/refractory (RR) disease is becoming increasingly complex. This educational initiative is designed to improve the ability of APs to provide high-quality care for patients with RRMM. It includes three expert clinical dialogues, downloadable slides, links to resources, and downloadable patient education materials.

Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Optimizing Use of Current Options

Review how to optimize the use of current therapies, including incorporating risk-adapted treatment strategies and keeping up to date with evolving guidelines for evaluating treatment response.

Posted: July 31, 2019 / Expires: July 31, 2020

0.5 Credit

Estimated time to complete: 30 minutes

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This activity is supported by educational grants from AbbVie Inc. and Celgene Corporation.


Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Preparing for Novel Agents

Discover the practice-changing implications of novel mechanisms of action, new combinations, and new administration options.

Posted: July 31, 2019 / Expires: July 31, 2020

0.5 Credit

Estimated time to complete: 30 minutes

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This activity is supported by educational grants from AbbVie Inc. and Celgene Corporation.


Enhancing Shared Decision Making in Relapsed/Refractory Multiple Myeloma (RRMM)

Learn how to incorporate patient-centered communication and shared decision making in your practice, thereby improving patient and caregiver adherence, satisfaction, and engagement.

Posted: July 31, 2019 / Expires: July 31, 2020

0.5 Credit

Estimated time to complete: 30 minutes

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This activity is supported by educational grants from AbbVie Inc. and Celgene Corporation.


 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.